Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosisBarbara Delage, Peter W. Szlosarek|Cell Death and Disease|2012Cited by 151
Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian CancerNelofer Syed, Tim Crook, Helen M. Coley et al.|Cancer Research|2011Cited by 60
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancersKwang‐Yu Chang, Li-Tzong Chen, Shalini S. Yadav et al.|OncoImmunology|2021Cited by 44
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance MechanismsPeter W. Szlosarek, Michael Sheaff|JTO Clinical and Research Reports|2020Cited by 30
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa Phillips, Peter W. Szlosarek|Pharmacological Reports|2023Cited by 5